Figure 4.

TIPE2-deficient MDSCs enhance ferroptosis-induced tumor growth inhibition via reprogramming the immune microenvironment. (a) A schematic representation of the experimental design; C57BL/6 mice were injected s.c. with LLC cells on day 0. Then, IKE (10mg/kg) was injected i.p. at day 8 till day 21. (b) The tumor volume of LLC C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (c) The tumor weight of LLC C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (d) The body weight of LLC C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (e) A schematic representation of the experimental design, C57BL/6 mice were injected s.c. with B16F10 cells on day 0. Then, IKE (10 mg/kg) was injected i.p. at day 8 till day 21. (f) The tumor volume of B16F10 C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (g) The tumor weight of B16F10 C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (h) The body weight of B16F10 C57BL/6 mice (n = 3 mice/group) treated with IKE for 2 weeks. Mean ± SD are shown. (i) The percentages of immune cells in tumor tissues extracted from the LLC TB mice treated with IKE: MDSCs, PMN-MDSCs, M-MDSCs, Treg cells, DCs, macrophages, B cells, NK cells, CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, were discovered by flow cytometry. MDSCs were CD45⁺ CD11b⁺ Gr-1⁺ cells; PMN-MDSCs were CD45⁺ CD11b⁺ Ly6C⁻Ly6G⁺ cells; M-MDSCs were CD45⁺ CD11b⁺ Ly6C⁺ Ly6G⁻ cells; Treg cells were CD45⁺ CD3⁺ CD4⁺ CD25⁺ CD127⁻ cells; DCs were CD45⁺ CD11b⁺ CD11c⁺ cells; macrophages were CD45⁺CD11b⁺ F4/80⁺ cells; B cells were CD45⁺CD3⁻ CD19⁺ cells; and NK cells were CD45⁺ CD3⁻ NK1.1⁺ cells; CD3⁺ T cells were CD45⁺ CD3⁺ cells; CD4⁺ T cells were CD45⁺ CD3⁺CD4⁺ CD8⁻ cells; CD8⁺ T cells were CD45⁺CD3⁺CD4⁻CD8⁺ cells. Mean ± SD are shown. (b–d,f–i) Data are expressed as ***, p ≤ 0.001, or ns, no significant difference.